Dosing regimen and the frequency of macular hemorrhages in neovascular age-related macular degeneration treated with ranibizumab

Retina

Volumn 30, Issue 9, 2010, Pages 1376-1385

  Barbazetto, Irene ^a   Saroj, Namrata ^b   Shapiro, Howard ^b   Wong, Pamela ^b   Freund, K Bailey ^a  

^a VITREOUS RETINA MACULA CONSULTANTS OF NEW YORK   (United States)

^b GENENTECH INC   (United States)

Author keywords

age related macular degeneration; choroidal neovascularization; macular hemorrhage; ranibizumab

Indexed keywords

RANIBIZUMAB; VERTEPORFIN;

ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; HUMAN; MAJOR CLINICAL STUDY; MORBIDITY; MULTICENTER STUDY; PHOTODYNAMIC THERAPY; RANDOMIZED CONTROLLED TRIAL; RETINA MACULA AGE RELATED DEGENERATION; RETINA MACULA HEMORRHAGE; RISK FACTOR; SUBRETINAL NEOVASCULARIZATION;

ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL; ANTICOAGULANTS; CHOROIDAL NEOVASCULARIZATION; DOUBLE-BLIND METHOD; FLUORESCEIN ANGIOGRAPHY; HUMANS; INCIDENCE; INTRAOCULAR PRESSURE; INTRAVITREAL INJECTIONS; MACULAR DEGENERATION; OPHTHALMOSCOPY; PHOTOCHEMOTHERAPY; PLATELET AGGREGATION INHIBITORS; RETINAL HEMORRHAGE; TOMOGRAPHY, OPTICAL COHERENCE; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VISUAL ACUITY;

EID: 78049238545     PISSN: 0275004X     EISSN: None     Source Type: Journal    
DOI: 10.1097/IAE.0b013e3181dcfb0b     Document Type: Article

References (11)

1. Davis MD, Gangnon RE, Lee LY, et al. The Age-Related Eye Disease Study severity scale for age-related macular degeneration: AREDS Report No. 17. Arch Ophthalmol 2005; 123:1484-1498. (Pubitemid 41626684)
2. Yannuzzi LA, Negrao S, Iida T, et al. Retinal angiomatous proliferation in age-related macular degeneration. Retina 2001; 21:416-434. (Pubitemid 32971350)
3. Scupola A, Coscas G, Soubrane G, Balestrazzi E. Natural history of macular subretinal hemorrhage in age-related macular degeneration. Ophthalmologica 1999; 213:97-102. (Pubitemid 29049394)
4. Avery RL, Fekrat S, Hawkins BS, Bressler NM. Natural history of subfoveal subretinal hemorrhage in age-related macular degeneration. Retina 1996;16:183-189. (Pubitemid 26190846)
5. Mozaffarieh M, Sacu S, Benesch T, Wedrich A. Subretinal hemorrhages secondary to age-related macular degeneration: psychological and vision-related functional perspectives. Ophthalmologica 2008;222:199-204. (Pubitemid 351733210)
6. Rosenfeld PJ, Brown DM, Heier JS, et al. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med 2006;355:1419-1431. (Pubitemid 44511557)
7. Brown DM, Michels M, Kaiser PK, Heier JS, Sy JP, Ianchulev T. Ranibizumab versus verteporfin photodynamic therapy for neovascular age-related macular degeneration: two-year results of the ANCHOR study. Ophthalmology 2009;116:57-65.e5.
8. Brown DM, Kaiser PK, Michels M, et al. Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N Engl J Med 2006;355:1432-1444. (Pubitemid 44511558)
9. Regillo CD, Brown DM, Abraham P, et al. Randomized, double-masked, sham-controlled trial of ranibizumab for neovascular age-related macular degeneration: PIER Study year 1. Am J Ophthalmol 2008;145:239-248.
10. Goverdhan SV, Lochhead J. Submacular haemorrhages after intravitreal bevacizumab for large occult choroidal neo-vascularisation in age-related macular degeneration. Br J Ophthalmol 2008;92:210-212. (Pubitemid 351224096)
11. Gaudreault J, Fei D, Beyer JC, et al. Pharmacokinetics and retinal distribution of ranibizumab, a humanized antibody fragment directed against VEGF-A, following intravitreal administration in rabbits. Retina 2007;27:1260-1266 (Pubitemid 350211535)